Novo Nordisk has entered into a new strategic partnership with Amazon Web Services (AWS) to accelerate drug discovery and modernise its operations through agentic AI and cloud technologies.
As part of the collaboration, Novo Nordisk and AWS have created a co-innovation hub in London where engineers and scientists from both companies are combining AWS AI technologies with Novo Nordisk data and insights. The initiative aims to shorten the journey from identifying a drug target to administering the first dose in humans.
“Partnering with AWS is about making AI a driver of innovation across Novo Nordisk,” said Mike Doustdar, president and CEO of Novo Nordisk.
“By combining our scientific expertise with AWS’ tools and purpose-built services for the life sciences industry, while also creating a dedicated co-innovation hub within our existing facility in London, we are accelerating discovery and developing responsible AI solutions that will create real progress for people living with serious chronic diseases,” he added.
Under the agreement, Novo Nordisk has selected AWS as its preferred cloud provider and strategic AI partner, bringing together Novo Nordisk’s therapeutic knowledge across chronic diseases and AWS’s cloud and AI services, secure and scalable infrastructure, and life sciences technologies.
Novo Nordisk said the collaboration has already delivered measurable results, including reducing clinical documentation time and empowering more than 25,000 employees to boost productivity.
The new agreement also includes use of services such as Amazon Bio Discovery and Amazon Bedrock to identify drug targets, design new therapies faster, and connect genomic, imaging and clinical data so that breakthroughs in early research can shape clinical trial design.
In addition, Novo Nordisk will leverage Amazon Bedrock AgentCore to drive efficiencies across its operations through AI agents.
“Every part of our work with Novo Nordisk comes back to one thing: getting the right medicine to patients, faster,” said Matt Garman, CEO, AWS.
“Novo Nordisk has chosen AWS as their strategic AI partner to fundamentally change how medicines are discovered and developed using services such as Amazon Bio Discovery and Amazon Bedrock. We’re excited to partner with Novo Nordisk so that these technologies, AWS Forward Deployed Engineers, and Novo Nordisk’s industry-leading science teams can help compress drug discovery timelines, securely process complex datasets, and scale findings across therapeutic areas,” Garman added.
Novo Nordisk also collaborates with several Amazon businesses serving the healthcare sector, including Amazon Pharmacy, Amazon Ads and Amazon One Medical, as part of efforts to transform how therapies are marketed and delivered to patients.
